tbuckley/cabot-search huggingface dataset:
1935P Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Authors: S. Pérez Fernandez, J. Hernando Cubero, A. Garcia Alvarez, T. Alonso Gordoa, I. Ceballos Lenza, G. Marquina Ospina, P. Jimenez Fonseca, P. Ayala de Miguel, M.L. Isidro San Juan, M. Plana Serrahima, E. Gallardo, C. Lopez, N. Martinez Lago, S.E. Campos Ramirez, V. Rodríguez-Morón, C. Salva de Torres, M. Roca, S. Marínez Badal, M. Llanos-Munoz, J. Capdevila Castillon
Journal: Annals of Oncology (2024)
1860P The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia
Authors: Y. Hsia, C.H. Chiang, Y-C. Chang, T. Tamdin, K-Y. Chi, Y. Chang, C-L. Hsiao, C-H. Chiang
Journal: Annals of Oncology (2024)
1969P Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Authors: R.K. Jain, M. Chatwal, J. Chadha, E. Oschmann, S. Mizelle, T. Poehlman, W. Fan, Y. Kim, J. Dhillon, X. Wang, J. Zhang, J-A. Guevara, G.P. Sonpavde
Journal: Annals of Oncology (2024)
1802P Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly extensive disease small cell lung cancer (ED-SCLC) patients (pts): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs)
Authors: K. Yamamoto, K. Hirano, A. Hata, Y. Yamanaka, T. Sumi, M. Tamiya, Y. Sato, Y. Oya, K. Hamai, N. Katakami, K. Iwasaki, K. Kokubo, A. Igarashi
Journal: Annals of Oncology (2024)
1833P JUMP_START: Optimization of multiprofessional care for young patients with colorectal cancer
Authors: K. Xu, C. Flock, K. Kaunath, N. Schmitt, C. Bienen, J. Walther, J. Robl, K. Mehlis, A. Züger, E. Klein, J. Winnefeld, M. Kecht, D. Jäger, G.M. Haag, F. Pawlowski, E.C. Winkler, T.J. Bugaj, B.C. Köhler
Journal: Annals of Oncology (2024)
1806P Clinical characteristics and management of small cell lung cancer long survivors
Authors: E. Gobbini, M.H. Diallo, D. Pasquier, S. Schneider, C. Chouaid, D. Debieuvre, X. Quantin, C. Audigier Valette, G. Justeau, A.T. Stancu, A-C. Madroszyk Flandin, E. Pichon, L. Falchero, A. Vergnenegre, O. Bylicki, A. Baranzelli, L. Bosquet, M. Pérol, N. Girard
Journal: Annals of Oncology (2024)
1797P Association between baseline PD-L1 expression in circulating leukocytes, the presence of immune-related adverse events (irAEs) and survival outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC) from the CANTABRICO trial
Authors: A. Piedra, A. Guinart-Cuadra, M. Mulet, C. Zamora, J. Alejandre, S. Martinez Recio, A. Barba Joaquín, I.G. Sullivan, J. Serra López, M.D. Isla Casado, E. Arriola Aperribay, L.G. Paz-Ares, P. Diz Tain, A.L. Moreno Vega, Á. Callejo, S. Vidal, M. Majem
Journal: Annals of Oncology (2024)
1843P Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
Authors: D. Smussi, M. Carpani, S. Vetrugno, C. Catapano, E. Stucchi, A. Alberti, L. Lorini, S. Carnio, A. Berruti, D.L. Cortinovis, P. Di Pede, F. Citarella, L. Galli, S. Stragliotto, P. Ermacora, F. Roila, F. Zustovich, L.E. Velutti, G. De Feo, P. Bossi
Journal: Annals of Oncology (2024)
1836P Patient-reported health behaviors (PRHB) among 1850 patients enrolled in a remote patient monitoring (RPM) pathway
Authors: M.A. Franzoi, A. Di Meglio, M. di Palma, T. Grellety, E. Eithurbide Dachary, X. Artignan, E. Blanchard, A. Thirot Bidault, P. Lacombe, J. Rodriguez, A. Lemaire, L. Polastro, L. Caravella, J. Grosjean, C. Ferté, A. Diab, A.R. Ferreira, E. Basch, F. Scotté, I.V. Vaz Luis
Journal: Annals of Oncology (2024)
1827P Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Authors: M.C. Cursano, A.A. Valsecchi, F. Pantano, M. Di Maio, G. Procopio, A. Berruti, F. Bertoldo, M. Tucci, U. De Giorgi, D. Santini
Journal: Annals of Oncology (2024)
1817MO Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial
Authors: J. Ligibel, K. Ballman, L. mccall, P. Goodwin, A.C. Weiss, T. Crane, M. Irwin, C. Thomson, O. Hahn, P. Spears, D.L. Hershman, E.D. Paskett, J.O. Hopkins, V. Bernstein, V. Stearns, J. White, T.A. Wadden, E.P. Winer, L.A. Carey, A.H. Partridge
Journal: Annals of Oncology (2024)
1812TiP IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
Authors: C.M. Rudin, M.A. Salkeni, M. Gutierrez, H. Hayashi, J. Thompson, M. Arca, D. Hirose, J. Singh, J. Turner, Y. Zhang, T.K. Owonikoko
Journal: Annals of Oncology (2024)
1815O Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study
Authors: E. Blondeaux, V. Delucchi, E. Mariamidze, R. Bernstein Molho, A-S. Hamy-Petit, A. Ferrari, S. Linn, H.J. Kim, E. Agostinetto, S. Paluch-Shimon, A. Toss, A. Di Meglio, J. Balmaña, R. Yerushalmi, K.R. Rodriguez-Wallberg, I. Demeestere, H.A. Azim, F.A. Peccatori, A.H. Partridge, M. Lambertini
Journal: Annals of Oncology (2024)
1834P Accuracy of recommendations by a conversational Artificial Intelligence (AI) cancer mentor application (app): A multi-disciplinary, multi-institutional evaluation report
Authors: T. Golan, O. Purim, I. Iofin, D. Rosin, E. Sapir, M. Gatt, T. Charas, I. Wolf, B. Haikin, D.A. Vorobiof
Journal: Annals of Oncology (2024)
1831P Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Authors: A. Tarabay, A. Pages, R. Fostier, V. Delaye, A. Gravian, M. Aldea, D. Planchard, F. Scotté, S. Antoun, M. Merad
Journal: Annals of Oncology (2024)
1798P Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Authors: S. Moore, L.J. Zhan, J. Gill, D. Chowdhury, J. Reibel, D. Patel, K. Balaratnam, K. Khan, F. Al-Agha, S. Raptis, D. Akurang, A. Lo, M. Richardson, R. Rittberg, G. Kasymjanova, B.H. Lok, J. Agulnik, D. Dawe, P. Wheatley-Price, G. Liu
Journal: Annals of Oncology (2024)
1803P Analysis of samples from the SCLC REACTION trial: Discovery of biomarkers to optimize treatment
Authors: P. Lavaud, S. Hill, A. Clipson, G. Gulati, D. Morgan, S. Pearce, K. Simpson, D. Rothwell, J. Menis, A-M.C. Dingemans, B. Besse, C. Dive
Journal: Annals of Oncology (2024)
1828P A cross-sectional study investigating the current diagnostic &amp; therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Authors: S. Pilotto, A. Avancini, N. Giaj-Levra, G. Minuti, G. Pasqualini, F. Colonese, A. Di Federico, A. Fozza, M. Montrone, E. Olmetto, E. Pastorello, M.L. Reale, S.T. Riva, E. Roca, C. Sini, G. Viscardi, F. Passiglia
Journal: Annals of Oncology (2024)
1819MO Systemic inflammation, unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC)
Authors: A. Di Meglio, J. Havas, M. Pagliuca, M.A. Franzoi, D. Soldato, B. Pistilli, F. Joly Lobbedez, P.H. Cottu, O. Tredan, A. Bertaut, P. Ganz, J. Bower, A.H. Partridge, A-L. Martin, S. Everhard, S. Boyault, S. Broutin, S. Michiels, C. Sarre-Pradon, I.V. Vaz Luis
Journal: Annals of Oncology (2024)
1796P Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Authors: Y. Cheng, L. Han, L. Wu, J. Chen, H. Sun, G. Wen, Y. Ji, M. Dvorkin, J. Shi, M. Jia, X. Yang, S. Lechpammer, M. Chen, F. Yang, C. Hu, Q. Wang, C. Ling, J. Li, Y. Shan, J. Zhu
Journal: Annals of Oncology (2024)
1838P AI-based smart oncology follow-up system: Prospective application testing and enhancement of clinical efficacy
Authors: C. Xu, Y. Wang, Y. Hao, Q. Jian, Y. Zhu, Q. Wang, F. Pang, Z.S. Rong, D. Wang, D. Lv, H. Chen, K. Wang
Journal: Annals of Oncology (2024)
1840P Ready for digital health? A national mirror survey exploring the perspectives of both patients and healthcare professionals
Authors: F. Scotté, M. di Palma, C. Migala, A. Eche Gass, C. Cerisey, B. Clairaz, M-L. De Botton, L. Gueroult-Accolas, H. Drevot, V. Labonne, I. Krakowski, D. Mayeur
Journal: Annals of Oncology (2024)
1835P Multi-centre, randomised controlled trial of digital health cancer solution for cancer patients receiving chemotherapy
Authors: A. Michael, H. Thandar, P.C. Leonard, S. Popat, R. Patel, G. Kirby, M. Kelly, P. Ridley, R.A. Peck, U. Barthakur, A.H. Montazeri, R. Shah, R. Bowen, L. Smith, K. Bennett Eastely, S. Skene
Journal: Annals of Oncology (2024)
1813TiP Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Authors: V. Gambardella, A.F. Navarro Mendivil, J.M. Lopez-Picazo Gonzalez, P. Jain, G. Fernandez-Hinojal, M. De Miguel, J. Zugazagoitia, S. Gadgeel, S.A. Bhatti, A. Vilalta, E. Castanon Alvarez, P.F. Simoes da Rocha, S. Micallef, R. Frederiksen Franzen, L. Piggott, A. Bellon, E. Rodrigo Imedio, L.G. Paz-Ares
Journal: Annals of Oncology (2024)
1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial
Authors: H.A. Azim, S. Niman, A.H. Partridge, M. Ruggeri, M.A. Colleoni, C. Saura Manich, C. Shimizu, A. Satersdal, J.R. Kroep, K.A. Gelmon, F. Amant, A. Mailliez, H. Moore, T. Ferreiro, S. El-abed, R.D. Gelber, O. Pagani, F.A. Peccatori
Journal: Annals of Oncology (2024)
1830P Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Authors: S.H. Hutajulu, Y.K. Astari, M. Ucche, D.K. Paramita, M.S. Hardianti, K.W. Taroeno Hariadi, J. Kurnianda, I. Purwanto
Journal: Annals of Oncology (2024)
1841P Feasibility of wrist-worn health-tracker data to predict the need for therapy modifications in patients with metastatic cancer
Authors: A.S. Berghoff, D.F-X. Huber, L. Berchtold, B. Sunder-Plassmann, J.M. Berger, L. Gottmann, M. Korpan, M. Kleinberger, J.H. Fürst, N. Vladic, V. Sunder-Plassmann, M. Göksun, C. Englisch, A.M. Starzer, M. Preusser
Journal: Annals of Oncology (2024)
1848P Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience
Authors: O. Bas, L. Sert, O.Y. Balcik, M. Tokatli, N.E. Boyraz, G. Kavgaci, T.K. Sahin, D.C. Guven, Z. Arik, A. Isikdogan, M. Erman
Journal: Annals of Oncology (2024)
1824P Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Authors: F.G. Dall'Olio, L. Lawrance, W.S. Zrafi, S. Ammari, Y. Vassetsky, A. Bône, J. Dupont, P. Busson, P. Decazes, L. Friboulet, Y. Loriot, A. Italiano, N. Lassau, B. Besse
Journal: Annals of Oncology (2024)
1793P Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Authors: S. Moore, L.J. Zhan, D. Chowdhury, R. Rittberg, M-F. D’Amours, S. Raptis, D. Akurang, A. Lo, Y.J. Kim, F. Yu, S. Snow, M.S. Kuruvilla, M. Yan, V. Navani, J. Agulnik, D. Dawe, B.H. Lok, G. Liu, C. Ho, P. Wheatley-Price
Journal: Annals of Oncology (2024)
1816O A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Authors: H. Sakai, J. Tsurutani, Y. Ozaki, H. Ishiguro, K. Nozawa, T. Yamanaka, H. Kameoka, K. Matsumoto, T. Iwasa, M. Tokiwa, M. Tsuneizumi, Y. Miyoshi, C. Kitagawa, M. Yamamoto, Y. Takano, C.K. Imamura, Y. Chiba, D. Takiguchi, T. Ezumi, T. Takano
Journal: Annals of Oncology (2024)
1804P Atezolizumab plus chemotherapy followed by atezolizumab plus anlotinib in the first-line treatment for extensive-stage small cell lung cancer: A multicenter, single-arm, prospective real-world study
Authors: Y. Pan, X. Qian, H. Zhou, W. Jin, J. Chen, Y. Wang, Z. Zhang, H. Liu, Y. Jin, F. jiang, H. Liu
Journal: Annals of Oncology (2024)
1845P The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Authors: Z. Coyne, R. Sutradhar, V. Aghanya, Y. Kaliwal, Y. Niu, N. Liu, Y. Liu, M. Powis, G. Liu, J. Peppercorn, M.K. Krzyzanowska, L. Eng
Journal: Annals of Oncology (2024)
1837P Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium
Authors: C. Baldini, T. Grellety, R. Boulahssass, P. Soubeyran, E.G.C. Brain, L. Mourey, C. Dumas-Bonnetain, F. Canouï-Poitrine, R. Rivoirard, A. Diab, E. Nouhaud, M. Autheman, J.G. Fanton d'Andon, J. Ancillon, C. Ferté, C.P. Massard, F. Scotté, N. Bertrand
Journal: Annals of Oncology (2024)
1832P Physical condition is associated with quality of life in colorectal cancer survivors: Results from a Portuguese and Spanish cohort of patients
Authors: L.M.D.C. Soares Miranda, M. Romero-Elias, M. Silva, A. Peixoto, J. Mota, G. Macedo, S. Abreu, A. Ruiz-Casado
Journal: Annals of Oncology (2024)
1842P The experience of women with breast or gynecological cancer after participation in the online mindfulness-based cancer recovery program (eMBCR)
Authors: M-E. Gaignard, J. Stanic, D. Martin, R. Hilfiker, A. Bodmer, M. Ljuslin, K. Zaman, S.I. Labidi-Galy, A. Sarivalasis, S. Peters, P-Y. Dietrich, M. Eicher, G. Bondolfi, F. Jermann
Journal: Annals of Oncology (2024)
1794P Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Authors: L. Meder, C.I. Orschel, C. Bouchez, D. Stahl, R. Gholamipoorfard, M. Koker, M. Nill, J. Braegelmann, X. Zhao, C. Orschel, A. Florin, N. Abedpour, R. Büttner, H.C. Reinhardt, R.T. Ullrich
Journal: Annals of Oncology (2024)
1823P Significance of skeletal muscle measurement in cancer-associated cachexia screening
Authors: L. Gottmann, M. Kleinberger, J.H. Fuerst, M. Korpan, J.M. Berger, V. Sunder-Plassmann, C. Englisch, N. Vladic, L. Berchtold, I. Solano Henao, M. Göksun, H.C. Puhr, A.M. Starzer, M. Mair, J. Furtner, E.S. Bergen, A.S. Berghoff, M. Preusser
Journal: Annals of Oncology (2024)
1818MO Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC)
Authors: P. Lapidari, M. Lustberg, J. Havas, M. Pagliuca, C. Bousrih, C. Jouannaud, M. Fournier, W. Jacot, L. Vanlemmens, C. Kaderbhai, O. Tredan, C. Levy, A-L. Martin, C. Gaudin, G. Menvielle, M.A. Franzoi, I.V. Vaz Luis, A. Di Meglio
Journal: Annals of Oncology (2024)
1821MO Predictive biomarkers of dyspnea response to dexamethasone in cancer patients: A secondary analysis of the Alleviating Breathlessness in Cancer Patients with Dyspnea (ABCD) trial
Authors: D. Hui, S. Hanneman, K. Jennings, A. Ontai, S. Cron, E. Bruera
Journal: Annals of Oncology (2024)
1801P Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Authors: K.J. O'Byrne, Y. Zhang, J. Ouyang, W-C. Chou, C-H. Chou, J. Wu, O. Adelakun, T. Hollmann, J.A. Zeng, L. Corrella, M. Metzler, C. Green, R. Sarmiento, E. Lees, Y. Liu, L. Ojalvo, B. Wu
Journal: Annals of Oncology (2024)
1809P Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma
Authors: P. Cruz Castellanos, L. Gutierrez Sainz, L. Fernandez Franco, J. Rogado, X. Mielgo Rubio, A. Collazo Lorduy, B. Riesco Montes, C. Traseira Puchol, S. Simon, S. Falagán Martínez, L.E. Chara Velarde, A.M. Martin Fernandez, L. Cabezon Gutierrez, A. Lopez Martin, J.L. Sanchez Sanchez, S. Cerezo Gonzalez, A. Viana, J.R. Muñoz-Rodriguez
Journal: Annals of Oncology (2024)
1811TiP SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3
Authors: J. Sands, J. Henry, C. Meador, A. Spira, D. Mahadevan, G. McGregor, R. Laeufle, H. Zou
Journal: Annals of Oncology (2024)
1810P MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
Authors: C. de Rosa, C. Tuccillo, L. Amato, A. Ariano, A. Servetto, F. Papaccio, F. Ciardiello, F. Morgillo, C.M. Della Corte
Journal: Annals of Oncology (2024)
1759P Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor
Authors: J. Li, J. Zhang, Y. Zhang, H. Qiu, Y. Zhou, Z. Yongjian, X. Zhang, Y. Zhou, Y. Zhu, Y. Li, M. Wang, K. Shen, K. Tao, X. Wu, H. Wang, B. Zhang, J. Ling, Y. Ye, L. Shen
Journal: Annals of Oncology (2024)
1767P Pegylated liposomal doxorubicin in symptomatic desmoid tumor
Authors: K. Boye, A.T. Skeie, M.R. Kobbeltvedt, L. Hårklau, A.B. Mariathasan, G.H.N. Nguyen, I.V.K. Lobmaier, T. Hompland, I. Hompland
Journal: Annals of Oncology (2024)
1761P Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network
Authors: C. Cuvelier, M. Brahmi, I. Sobhani, B. Verret, A. Grancher, N. Penel, M. Toulmonde, W. Lahlou, H. Dupuis, L. Calavas, M. Muller, S. Watson, D. Bruyat, F. Poumeaud, L. Chaigneau, S. Manfredi, T. Lecomte, F. Bertucci, O. Bouche, V. Hautefeuille
Journal: Annals of Oncology (2024)
1775P Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
Authors: E. Rosenbaum, F. Ehrich, M. Bradic, C.M. Kelly, S. Movva, J. Chan, P. Chi, L. Banks, M. Dickson, M.L. Keohan, R.G. Maki, A. Reiner, M. Adamow, C. Antonescu, S. Singer, P. Wong, K. Panageas, W.D. Tap, R. Shen, S.P. D'Angelo
Journal: Annals of Oncology (2024)
1741P Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
Authors: P.G. Casali, S. Provenzano, C. Crico, C. Fabbroni, I. Pellegrini, G. Apollonio, M.R. Fiore, A. Gronchi, A. Luzzati, C. Morosi, C. Sangalli, V. Sanchini
Journal: Annals of Oncology (2024)
1770P Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Authors: G. D'Amato, A.J. Wagner, K.N. Ganjoo, S. Stacchiotti, H. Gelderblom, C.W. Ryan, E. Palmerini, V. Ravi, R. Saleh, A. Le Cesne, N.M. Bernthal, M. van de Sande, S. Narasimhan, B. Harrow, A. Saunders, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
Journal: Annals of Oncology (2024)
1771P Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)
Authors: S.P. Chawla, W. Isacoff, S. Jeffrey, N. Omelchenko, N.S. Chawla, A.D. Agarwal, G. Haroun, R. Carter, R. Reed, W. Swaney, F.L. Hall, N. Federman, P. Chang, P. Song, E.M. Gordon
Journal: Annals of Oncology (2024)
1780P Homologous recombination pathway in sarcomas: A novel opportunity of therapy?
Authors: M.D.C. Garijo Martínez, M. Amann Arevalo, A. Manzano Fernández, A. Casado Herraez, G. Marquina Ospina, P. Pérez Segura, L. Fernandez, L. Ortega, Y. Lopez Mateos, J.D. Benitez Fuentes, D. Morchón Araujo, J. Roldan Ruiz, J. Bartolomé Arcilla
Journal: Annals of Oncology (2024)
1772P Phosphoproteomic biomarker for afatinib response stratification in advanced chordoma
Authors: C. Stange, A. Schneider, C.B. Jensen, A. Sakhteman, M-V. Teleanu, P. Horak, S. Kreutzfeldt, M. Oles, C.E. Heilig, N. Punturi, L. Dolat, M. Resch, F. Hamood, C. Herold-Mende, D. Hübschmann, S. Wilhelm, D.M. Freed, M. The, S. Fröhling, B. Kuster
Journal: Annals of Oncology (2024)
1778P Clear cell sarcomas (CCS) express Gp100: A novel immune target for a bispecific T cell engager
Authors: E.F. Nassif Haddad, J. Smith, R. Lazcano, D. Ingram, K. Wani, M.S. Nakazawa, R. Ratan, J.A. Livingston, A.P. Conley, M.A. Zarzour, N. Somaiah, D. Araujo, V. Ravi, S. Patel, E. Keung, C.L. Roland, W-L. Wang, A. Lazar
Journal: Annals of Oncology (2024)
1742P Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Authors: P. Mascaró Baselga, G. Villacampa, V. Navarro Garces, A. Sebio Garcia, R.M. Alvarez, M.A. Sala Gonzalez, G. Marquina Ospina, J. Martinez Trufero, J.M. Cano, A. Redondo, A. Molina Diaz, K.S. Vega Cano, C. Salva de Torres, J.G. Yaringaño Cerna, P. Martínez-Albaladejo, A. de Torner Vidal, C.M. Cicala, J. Tabernero, C.M. Valverde Morales, C. Serrano
Journal: Annals of Oncology (2024)
1746P Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Authors: K. Tsuchihashi, H.S. Okuma, E. Baba, M. Takahashi, I. Kinoshita, M. Muto, M. Kamikura, R. Sadachi, T. Shibata, M. Ichimura, W. Sakamoto, Y. Hirata, K. Nakamura, K. Yonemori
Journal: Annals of Oncology (2024)
1785TiP PERELI, a phase II, open label, multicenter study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma
Authors: H. Nyström, N.A. Pedersen, N. Junker, A. Papakonstantinou, L. Hansson, D. Goplen, J. Wesche, A. Carneiro, K. Boye
Journal: Annals of Oncology (2024)
1756P A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma
Authors: J.A. Livingston, J. Gill, A.P. Conley, N. Somaiah, D. Araujo, R. Ratan, V. Ravi, M.A. Zarzour, R.S. Benjamin, S. Patel, N. Daw, D. Harrison, R. Gorlick, T. Otto, H. Lin, W-L. Wang, B. Amini, E. Kleinerman, N. Gordon
Journal: Annals of Oncology (2024)
1740P Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Authors: Y. Zhou, X. Niu, X. Guo, Z. Huang, W. Li, W. Liu, H. Xu, Y. You, C. Zhang, R. Zhuang
Journal: Annals of Oncology (2024)
1779P Deep learning tertiary lymphoid structures detection on HES/H&amp;E slides and association to survival outcome in sarcoma
Authors: L. Vanhersecke, Y. Rodriguez, P. Jacob, L. Gillet, J-E. Le Douget, J.M. Coindre, G. MacGrogan, K. von Loga, K. Schutte, A. Italiano
Journal: Annals of Oncology (2024)
1755P Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial
Authors: V. Laurence, C. Cordero, S. Dureau, N. Jehanno, G. Pierron, N. Gaspar, T. Valentin, G. Revon-Riviere, C. Lervat, S. Taque, N. Entz-Werle, L. Mansuy, D. Plantaz, M. Rios, L. Saumet, C. Verite, M-P. Castex, E. Thebaud, M. Brahmi, N. Corradini
Journal: Annals of Oncology (2024)
1781P Multi-omics of soft tissue sarcomas with complex karyotypes: Investigating genomic and transcriptomic differences between cell lines of the same subtype
Authors: M.R. Arrulo, G. Wells, M.J. Dunning, W.R. English, J.K. Rantala, S. Danson, R. Young, K. Sisley
Journal: Annals of Oncology (2024)
1764P Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
Authors: L.A. Schardt, C. Serrano, J.C. Trent, D. Krzeciesa, K. Newberry, A. Grassian, Y-K. Kang, P. Rutkowski, R.L. Jones, M. Heinrich, W.D. Tap, M.A. Pantaleo, M. von Mehren, B.S. Fletcher, T. Muehlenberg, S. George, O. Mir, S. Bauer
Journal: Annals of Oncology (2024)